Evidence map›Paper›PMID 35494031›Full record

ArticleFrontiers in oncology2022

Corrigendum: Efficacy and Safety of Tumor Treating Fields (TTFields) in Elderly Patients With Newly Diagnosed Glioblastoma: Subgroup Analysis of methe Phase 3 EF-14 Clinical Trial.

Zvi Ram, Chae-Yong Kim, Andreas F Hottinger, Ahmed Idbaih, Garth Nicholas, Jay-Jiguang Zhu

Erratum issuedAbstract readPublished Erratum
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Zvi RamDepartment of Neurosurgery, Tel Aviv Medical Center and Tel Aviv University School of Medicine, Tel Aviv, Israel.
Chae-Yong KimDepartment of Neurosurgery, Seoul National University College of Medicine, Seoul, South Korea.
Andreas F HottingerDepartment of Clinical Neuroscience, CHUV Lausanne University Hospital & University of Lausanne, Lausanne, Switzerland.
Ahmed IdbaihService de Neurologie 2-Mazarin, Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Service de Neurologie 2-Mazarin, Paris, France.
Garth NicholasDepartment of Medicine, University of Ottawa, Ottawa, ON, Canada.
Jay-Jiguang ZhuDepartment of Neurosurgery, University of Texas Health Science Center at Houston, Houston, TX, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fonc.2021.671972.].

Indexed as

efficacy and safetyelderly patientsnewly diagnosed glioblastomaphase 3 clinical trialquality-of-lifetemozolomideTTFieldsTumor Treating Fields

Identifiers

PMID35494031
PMCPMC9040518

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.